Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· March 3, 2026

Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

View original at finance.yahoo.com

Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations…

Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

CKD cases are projected to increase further over the forecast period (2025-2034) due to the aging population
80% confidence
The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations
80% confidence
KIM-1 and NGAL enable earlier, more precise detection of CKD than traditional methods, improving the potential for timely intervention and better patient outcomes
80% confidence
Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment
80% confidence
Despite improved outcomes, current therapies only delay progression and cannot halt or reverse CKD, highlighting a major and persistent unmet need
80% confidence
In 2024, there were approximately 82 million prevalent cases of CKD in the 7MM
80% confidence
No current medications can reverse CKD
80% confidence
The distribution of End-Stage Kidney Disease (ESKD) cases across the 7MM indicates that the number of patients on dialysis exceeds that of those receiving kidney transplants
80% confidence
Zibotentan/dapagliflozin combination has the potential to reduce mortality and delay the onset of end-stage kidney disease (ESKD)
80% confidence
In 2024, there were nearly 14.5 million total diagnosed cases of CKD in the 7MM
80% confidence
The CKD therapy market includes RAAS inhibitors as the standard of care and the rapidly growing use of SGLT-2 inhibitors such as FARXIGA and JARDIANCE as emerging front-line options
80% confidence
The CKD market size in the 7MM was approximately USD 4.8 billion in 2024 and is expected to increase further by 2034
80% confidence
The United States accounts for the largest market size of chronic kidney disease, in comparison to EU4 (Germany, Italy, France, and Spain), the UK, and Japan
80% confidence